Type 2 ‘cost effective’ drug unveiled
Xultophy (IDegLira) has been found to be more cost-effective when compared with current basal insulin intensification in people with uncontrolled type 2 diabetes.
The findings of the once-daily single injection combination of Tresiba (insulin degludec) and Victoza (liraglutide), were unveiled at the Diabetes UK Professional Conference in Glasgow by Novo Nordisk.
The analysis assessed the cost-effectiveness of IDegLira compared to an up-titration of insulin glargine U100, separate injections of liraglutide added to basal insulin (insulin glargine U100 or insulin detemir), or insulin glargine U100 in combination with three daily injections of insulin aspart (basal-bolus).
This analysis was performed from the perspective of the UK NHS over a lifetime horizon.
Melanie Davies, professor of diabetes medicine at the University of Leicester said: “In the UK, 69 per cent of people with type 2 diabetes treated with basal insulin do not achieve glycaemic control.
“It is useful for clinicians that cost-effective combination treatments such as IDegLira are available as they have been shown to help patients achieve optimal glycaemic targets and may help prevent complications.”
On average, in the UK, daily administration of IDegLira cost less and was more effective compared to the separate injections of liraglutide added to basal insulin or compared to basal-bolus regimens.
IDegLira was also cost-effective versus up-titration of insulin glargine U100, with a cost of £6,090 per quality-adjusted life year [QALY] gained, which is well below the UK threshold of £20,000 to £30,000 used by NICE.
QALYs are commonly used in health economic evaluations to measure the additional health benefits achieved.